Search research articles
Contact Us
Filters
Showing results (21-30 of 33) with videos related to
Page
of 4
Sort By:
Journal for Immunotherapy of Cancer
|
October 26, 2019
Avelumab monotherapy as first-line or second-line treatment in patients with metastatic renal cell carcinoma: phase Ib results from the JAVELIN Solid Tumor trial
Ulka Vaishampayan, Patrick Schöffski, Alain Ravaud, et al.
American Journal of Clinical Oncology
|
March 7, 2018
Impact of Trabectedin Interruption and Subsequent Rechallenge on Progression in Patients With Advanced Soft Tissue Sarcoma: Long-term Follow-up of the T-DIS trial
Nuria Kotecki, Axel Le Cesne, Emmanuelle Tresch-Bruneel, et al.
Anticancer Research
|
June 10, 2019
Brain Metastasis and Renal Cell Carcinoma: Prognostic Scores Assessment in the Era of Targeted Therapies
Ziad El Ali, Sylvie Rottey, Philippe Barthelemy, et al.
Journal of the National Cancer Institute
|
August 5, 2020
Clinical Implications of Body Mass Index in Metastatic Breast Cancer Patients Treated With Abemaciclib and Endocrine Therapy
Maria Alice Franzoi, Daniel Eiger, Lieveke Ameye, et al.
Liver Cancer
|
August 11, 2022
First-In-Human Effects of PPT1 Inhibition Using the Oral Treatment with GNS561/Ezurpimtrostat in Patients with Primary and Secondary Liver Cancers
James J Harding, Ahmad Awada, Gael Roth, et al.
Trends in Cancer
|
December 3, 2025
The evolving landscape of brain metastasis: volume II
Manuel Valiente, Carey Anders, Adrienne Boire, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)
|
April 30, 2021
A Phase I Study of an IDO-1 Inhibitor (LY3381916) as Monotherapy and in Combination With an Anti-PD-L1 Antibody (LY3300054) in Patients With Advanced Cancer
Nuria Kotecki, Perrine Vuagnat, Bert H O'Neil, et al.
Oral Oncology
|
May 13, 2026
Efficacy of buparlisib according to PIK3CA mutation status in recurrent or metastatic head and neck squamous cell carcinoma: A multicenter phase II trial
Thibault Gauduchon, Laurence Digue, Céline Ferlay, et al.
Journal for Immunotherapy of Cancer
|
May 24, 2025
Avelumab-based neoadjuvant therapy in patients with muscle-invasive bladder cancer (AURA Oncodistinct-004): a phase 2 multicenter clinical trial
Jérémy Blanc, Aurélien Carnot, Philippe Barthélémy, et al.
British Journal of Cancer
|
August 26, 2020
A Phase 1 dose-escalation study to evaluate safety, pharmacokinetics and pharmacodynamics of AsiDNA, a first-in-class DNA repair inhibitor, administered intravenously in patients with advanced solid tumours
Christophe Le Tourneau, Jean-Pierre Delord, Nuria Kotecki, et al.
Page
of 4
Search research articles
Search
Showing results (21-30 of 33) with videos related to
Sort By:
Page
of 4
Journal for Immunotherapy of Cancer
|
October 26, 2019
Avelumab monotherapy as first-line or second-line treatment in patients with metastatic renal cell carcinoma: phase Ib results from the JAVELIN Solid Tumor trial
Ulka Vaishampayan, Patrick Schöffski, Alain Ravaud, et al.
American Journal of Clinical Oncology
|
March 7, 2018
Impact of Trabectedin Interruption and Subsequent Rechallenge on Progression in Patients With Advanced Soft Tissue Sarcoma: Long-term Follow-up of the T-DIS trial
Nuria Kotecki, Axel Le Cesne, Emmanuelle Tresch-Bruneel, et al.
Anticancer Research
|
June 10, 2019
Brain Metastasis and Renal Cell Carcinoma: Prognostic Scores Assessment in the Era of Targeted Therapies
Ziad El Ali, Sylvie Rottey, Philippe Barthelemy, et al.
Journal of the National Cancer Institute
|
August 5, 2020
Clinical Implications of Body Mass Index in Metastatic Breast Cancer Patients Treated With Abemaciclib and Endocrine Therapy
Maria Alice Franzoi, Daniel Eiger, Lieveke Ameye, et al.
Liver Cancer
|
August 11, 2022
First-In-Human Effects of PPT1 Inhibition Using the Oral Treatment with GNS561/Ezurpimtrostat in Patients with Primary and Secondary Liver Cancers
James J Harding, Ahmad Awada, Gael Roth, et al.
Trends in Cancer
|
December 3, 2025
The evolving landscape of brain metastasis: volume II
Manuel Valiente, Carey Anders, Adrienne Boire, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)
|
April 30, 2021
A Phase I Study of an IDO-1 Inhibitor (LY3381916) as Monotherapy and in Combination With an Anti-PD-L1 Antibody (LY3300054) in Patients With Advanced Cancer
Nuria Kotecki, Perrine Vuagnat, Bert H O'Neil, et al.
Oral Oncology
|
May 13, 2026
Efficacy of buparlisib according to PIK3CA mutation status in recurrent or metastatic head and neck squamous cell carcinoma: A multicenter phase II trial
Thibault Gauduchon, Laurence Digue, Céline Ferlay, et al.
Journal for Immunotherapy of Cancer
|
May 24, 2025
Avelumab-based neoadjuvant therapy in patients with muscle-invasive bladder cancer (AURA Oncodistinct-004): a phase 2 multicenter clinical trial
Jérémy Blanc, Aurélien Carnot, Philippe Barthélémy, et al.
British Journal of Cancer
|
August 26, 2020
A Phase 1 dose-escalation study to evaluate safety, pharmacokinetics and pharmacodynamics of AsiDNA, a first-in-class DNA repair inhibitor, administered intravenously in patients with advanced solid tumours
Christophe Le Tourneau, Jean-Pierre Delord, Nuria Kotecki, et al.
Page
of 4